Review Article

Managing Agitation Associated with Schizophrenia and
Bipolar Disorder in the Emergency Setting
Scott L. Zeller, MD*† *Alameda Health System, Department of Psychiatric Emergency Services, Oakland,
Leslie Citrome, MD, MPH‡ California

University of California-Riverside, Department of Psychiatry, Riverside, California

New York Medical College, Department of Psychiatry and Behavioral Sciences,
Valhalla, New York

Section Editor: Michael P. Wilson, MD, PhD
Submission history: Submitted September 23, 2015; Accepted December 10, 2015
Electronically published March 2, 2016
Full text available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2015.12.28763

Introduction: Patient agitation represents a significant challenge in the emergency department
(ED), a setting in which medical staff are working under pressure dealing with a diverse range of
medical emergencies. The potential for escalation into aggressive behavior, putting patients, staff,
and others at risk, makes it imperative to address agitated behavior rapidly and efficiently. Time
constraints and limited access to specialist psychiatric support have in the past led to the strategy
of “restrain and sedate,” which was believed to represent the optimal approach; however, it is
increasingly recognized that more patient-centered approaches result in improved outcomes. The
objective of this review is to raise awareness of best practices for the management of agitation in the
ED and to consider the role of new pharmacologic interventions in this setting.

Discussion: The Best practices in Evaluation and Treatment of Agitation (BETA) guidelines
address the complete management of agitation, including triage, diagnosis, interpersonal
calming skills, and medicine choices. Since their publication in 2012, there have been further
developments in pharmacologic approaches for dealing with agitation, including both new agents
and new modes of delivery, which increase the options available for both patients and physicians.
Newer modes of delivery that could be useful in rapidly managing agitation include inhaled, buccal/
sublingual and intranasal formulations. To date, the only formulation administered via a non-
intramuscular route with a specific indication for agitation associated with bipolar or schizophrenia
is inhaled loxapine. Non-invasive formulations, although requiring cooperation from patients, have
the potential to improve overall patient experience, thereby improving future cooperation between
patients and healthcare providers.

Conclusion: Management of agitation in the ED should encompass a patient-centered approach,
incorporating non-pharmacologic approaches if feasible. Where pharmacologic intervention is
necessary, a cooperative approach using non-invasive medications should be employed where
possible. [West J Emerg Med. 2016;17(2):165–172.]

INTRODUCTION (ED) visits by patients with psychiatric disorders, and requires
Individuals with bipolar disorder or schizophrenia are immediate action to prevent escalation to a level that could
vulnerable to episodes of agitation, which can be defined put patients, staff, and others at risk.1 As specialist psychiatric
as excessive verbal and motor behavior, especially during support other than social work services is often not available
exacerbations of their disease.1 Agitation associated with in the emergency setting, agitated patients may often need to
psychosis is a frequent reason for emergency department be medically evaluated and treated by emergency physicians.

Volume XVII, no. 2 : March 2016 165 Western Journal of Emergency Medicine

The physician should.” “schizophrenia.11-18 PANSS-EC and BARS have Guidelines are available to direct clinicians in all been successfully used as primary outcome measures in the aspects of agitation management from triage through to commercial development of several agents for the indication of pharmacologic choices. the five-item Positive and Negative Syndrome Scale injuries. the Medical Evaluation and Triage restraint and seclusion approach. severe headache.10 Identifying the etiology therefore represents injuries.10 Western Journal of Emergency Medicine 166 Volume XVII. extreme muscle stiffness deal with agitation occurring in association with dementia. however. while for others.3 From the patient’s perspective. and vulnerable. such as the intensive care unit. Patients with loss of memory It is recognized that physicians working in the ED must also or disorientation.8-10 In addition. overt trauma. no. the Project BETA guidelines were published by the American however. medical for the management of agitation in the ED. with a history of de-escalation of the agitated patient. When pharmacologic intervention agitation associated with schizophrenia and/or bipolar mania.6 or occurring in In the past. their presentation approaches. compounding problems of overcrowding immediate need to calm the patient to avoid escalation. seizures. The aim purposes and is also useful in a non-medical setting. Guideline Overview psychiatric medical condition or primarily due to a mental Various guidelines exist for the management of agitation. such as bipolar disorder.10 Abnormal vital signs. identify the underlying DISCUSSION etiology of the agitation – whether due to an underlying non. becomes high and a patient remains uncooperative. verbal frightened.5 disorder – before deciding on an appropriate course of action some of which provide direction for agitation associated with and possible pharmacologic intervention. delirium. levels should also be obtained. or difficulty in breathing should be scope of this review. searched. heat intolerance. attempts at de-escalation should be made and Treatment of Agitation (BETA) guidelines with the addition at this stage in order to gain the patient’s cooperation and of data on new pharmacologic interventions that were identified participation in the evaluation. or weakness. slurred speech. Additional data included in the review are based on and increased behavioral support if the risk of violent behavior product prescribing information. 2 : March 2016 .10 Where possible. psychopharmacologic traumatic experiences. and to consider evaluation and triage should include a brief history and vital the role of new pharmacologic interventions for patients with signs. of this narrative review is to raise awareness of best practices For agitated patients presenting in the ED. A negative experience at this stage can potentially Conditions of Participation for Hospitals include mandatory influence their future cooperation with healthcare workers regulations on the use of seclusion and restraint. these areas are beyond the new-onset psychosis. Some patients may require medication. the approach guidance on various aspects of patient management including does not recognize that many affected individuals are medical evaluation and triage.1 providing detailed outcomes. infection. this approach is associated with many negative Association for Emergency Psychiatry.2 a particular disorder. In addition. sedation can mask an underlying (PANSS) Excited Component (EC). an individual in restraints may take a substantial amount including the single-item Behavioral Activity Rating Scale of time.3. the Centers for Medicaid Services systems. psychotic disorders. where possible. substance abuse/withdrawal. agitated patient frequently involved restraint and seclusion. There may. so it is favored for purely pragmatic the patient and physician with treatment alternatives.” “bipolar. oxygen levels and blood glucose agitation associated with bipolar disorder or schizophrenia. unintentional weight loss. is deemed necessary. For the medical profession. fragile. sedated patient.” and “emergency department. unequally dilated pupils.2. although perceived by Agitation can be caused by disparate medical and many to be efficient. immediately evaluated by a clinician.” Articles were then hand evaluation. and the more complex condition.” “emergency assessment to calm them enough to allow a thorough care. thereby hindering accurate diagnosis.3. and it increases the length of time that individuals a significant challenge.10 information contained within the Best practices in Evaluation If feasible. however. Furthermore. or hemiparesis also warrant The content of this narrative review was based on immediate evaluation.7 In 2012. and drug abuse.Managing Schizophrenia and Bipolar Disorder Agitation Zeller et al. it is often associated with staff and depression. and the use and avoidance of seclusion and in the ED may be their first experience in mental healthcare restraint.4 The process of the “takedown” to place Rating scales have been developed to measure agitation. an array of therapeutic options BARS is simple to use and does not require the participant/ administered via different routes now exists. and jeopardize future management of a potentially serious underlying condition. psychiatric assessment. be through literature searches of PubMed using combinations of the instances where patients require medication during the search terms “agitation. and boarding.2 Overt Agitation Severity Scale. METHODS lack of coordination. restraint. which is made more difficult by the remain in the ED. standard practice for intervening with an a particular setting. providing both patient to answer questions. is resource intensive as there is a psychiatric conditions including head trauma. during which staff are at high risk of assaults and (BARS). thyroid requirement for one-to-one observation of a restrained or disease.

19 become necessary.3. For example. and to allow assessment. can also be useful. necessitating dosage adjustments. but instead it should aim to pharmacologic interventions represent only one part of establish a reasonable differential diagnosis. Sleeping stops staff from performing other duties. the goal The need for additional staff for the restraint procedure of pharmacologic intervention should be to calm the patient and subsequent observation is time consuming.4 Reduced ED boarding can increase doses and more frequent administration of medication may hospital revenue if bed capacity is effectively managed. avoiding sleep if possible. for a general medical condition should aim to identify the offering choices and optimism. toileting. other cognitive impairment.2 hours in the ED compared with those not the agitation becomes markedly more pronounced. etc. and others at increased risk of harm. cases. non-verbal interventions.2 However.3 Key aspects underlying condition would influence subsequent treatment of de-escalation include: respecting a patient’s personal decisions. a brief evaluation should be conducted onset oral medications – may be more acceptable to patients to establish the most likely cause of the agitation. Furthermore. the ED.2 Non-Pharmacologic Management When choosing the optimal treatment. putting the patient.20 however. assistance in or one who has been sedated. damage short. communicating simply patients with a concerning past medical history. however. costs. agitation can be related to safety of the patient and others. as this approach is associated with many negative where possible the underlying etiology should be targeted. and staff and patient patient has delirium. etc.9 In many than traditional injectable formulations. as it can be more which increases the burden on available resources (such challenging to admit or transfer a recently restrained patient as the need for one-to-one observation.9 Of note. outcomes. attempts should be made to establish if the including reduced resource use. a known psychiatric condition. or another The advantages and disadvantages of non-pharmacologic cause. As discussed Severe agitation can preclude the ability for emergency later. head trauma.) and avoided. Furthermore. is outside the normal ranges of psychiatric disease. where possible.9 verbal interventions and de-escalation. and can delay appropriate disposition. avoiding provocation.3 As part of this strategy. establishing verbal contact and should be suspected for cases of new-onset agitation and for providing orientation and reassurance.10 involuntary intervention has been necessary. and develop a managed through non-pharmacologic approaches.). identifying the patient’s wants and feelings. no. setting clear limits.8. voluntary medication Psychiatric Assessment and environment planning. delirium.19 or withdrawal. Patients who have or over-sedated patients can require additional monitoring. the provisional An important underlying principle of the Project diagnosis should be taken into account (intoxication. infection. When the patient is calm enough – either as a result approaches are outlined in Table 2. injuries – both physical and Consideration should also be given to the timing and extent psychological – often occur during restraint.and long-term patient–physician relationships. Elderly patients pose special challenges in negative consequences that extend beyond the period during terms of potential comorbidities and potential drug–drug which the patient is restrained. require changes in organizational culture and staff combined with verbal reports from other team and family training. The Instead of restraint. initial attempts to Project BETA guidelines recommend that patients should calm the patient should focus on non-coercive approaches be involved in the process of selecting the drug type and Volume XVII. and verbal de-escalation (Table 1). identify issues the overall approach. establishment of collaborative is an important aspect of triage and initial evaluation. and debriefing the patient if most likely underlying causes. A workup listening to what the patient is saying. if additional 4. e. some physicians to conduct a complete psychiatric evaluation at of the newer modes of administration – inhalation and rapid- the outset.8 For patients and staff. or if the onset and concisely. intoxication injuries.4. delaying and use and a longer time spent in the ED. and better patient–physician relationships. restraint can interactions.9 Next. in situations where medication is taken voluntarily. for many individuals some pharmacologic treatment will be necessary. BETA guidelines is that seclusion and restraint should be psychiatric illness. Taking these factors into account.Zeller et al.000 adults treated in use can allow the agitation to escalate. use of restraint resulted in patients spending an staff. however. of verbal de-escalation or initial medication – a formal psychiatric evaluation should be conducted. the benefits are widespread.g. Early and excessively aggressive pharmacologic Restraining patients can also result in additional resource intervention can mask underlying conditions. members. delays in medication a prospective evaluation of over 1. the initial assessment can be conducted through visual Implementation of non-coercive approaches may observation of the patient during attempts at de-escalation. 2 : March 2016 167 Western Journal of Emergency Medicine . Agitation arising from a general medical condition space. been sedated also spend longer in the ED. costly. as an relationship. Managing Schizophrenia and Bipolar Disorder Agitation Determining whether there is a known psychiatric illness involving verbal engagement. higher requiring restraint. In some cases. which can have of medication. such as suitable treatment and disposition plan. the goal Pharmacologic Management of an emergency psychiatric assessment is not necessarily Management of agitation is multifaceted and to obtain a definitive diagnosis. in impeding accurate diagnosis.

24 This rapid onset of prevent escalation and improve the experience of patients.2 If. cooperate with taking oral medications. over intramuscular formulations.27 and aripiprazole28 bipolar disorder or schizophrenia. such as antipsychotics ziprasidone.22. Table 2. in the case and ziprasidone)26–28 and bipolar mania (olanzapine and of acute withdrawal from alcohol or benzodiazepines the aripiprazole)27. the addition of a benzodiazepine is agents are approved by the FDA for treatment of acute agitation recommended over an increased dose of the same antipsychotic associated with schizophrenia (aripiprazole. e. and preservation of use of force to immobilize the patient can result in mental the physician–patient relationship.g. the control of aggressive behavior. and can occur 12–24 Medications commonly used in the management of acute hours after administration.25 The occurrence of adverse effects agitation include first. oculogyric crisis. and they also vary in terms of strength they have experienced an acute dystonic reaction.S. and cannot remain in a locked seclusion room without actively trying to injure themselves.21 immobilization. The first-generation led to the recommendation that non-invasive formulations injectable antipsychotic haloperidol has long been used in the should be used in situations where the patient is able to treatment of agitation in schizophrenia. this is not a trivial consideration. and akathisia. antipsychotics are preferred have more favorable extrapyramidal side-effect profiles over benzodiazepines because they address the underlying than haloperidol while providing similar effect sizes for the psychosis. and cannot tolerate or remain in a quiet unlocked room Restraint If patients are considered an imminent danger to themselves. Food and Drug Administration (FDA) patients may be less willing to take medicines. generation antipsychotics in guidelines.2 When delivered via cooperate. peak plasma levels of haloperidol some cooperation from patients but have the potential to are reached in ~20 minutes (Table 3). of the experimental evidence supporting their use. reliability. Behavioral intervention Patient scenario Verbal de-escalation Should be attempted in all patients Quiet unlocked room Patients in whom de-escalation alone was insufficient to reduce dangerousness enough to allow to remain in general care areas.28 and they are now recommended over the first- preferred medication intervention is a benzodiazepine. as it is estimated One of the key disadvantages of intramuscular injections that approximately half of all patients with schizophrenia have a is that patients may resist.and long-term patient–physician • May not be effective in all patients relationships • Requires some co-operation from the patient • Reduces staff and patient injuries associated with restraint and sedation • Reduces resource (clinical and staff) use administration route if possible. risking injury to healthcare providers. For patients Intramuscular preparations of the second-generation with agitation associated with a psychiatric disorder. If the patient is able to extrapyramidal symptoms. these are preferred including laryngospasm. however. including inadvertent needlestick injuries. Advantages Disadvantages • Facilitates better short. an initial dose of an antipsychotic does reduction of agitation. or addition of a second antipsychotic. including lengthened electrocardiogram QTc interval. circulation through the muscle’s vasculature.Managing Schizophrenia and Bipolar Disorder Agitation Zeller et al. 2 : March 2016 . Furthermore.2 lorazepam. resulting in the need for manual comorbid drug.23 Dystonic reactions.2 Non-invasive formulations require at least intramuscular injection.2 Moreover. and torticollis. Behavioral interventions for different scenarios involving patient agitation.2.29 Intramuscular injections of these not control the agitation.and second-generation Western Journal of Emergency Medicine 168 Volume XVII. such as these is an important consideration because they and benzodiazepines. no. olanzapine. action must be balanced against haloperidol’s adverse-event and could be considered when negotiation is possible. particularly if approval for this use. providing The disadvantages of intramuscular injections have the potential for rapid onset of action. Desirable features of antipsychotics are rapid onset. Table 1.23 Intramuscular injection trauma that has the potential to negatively affect immediate enables direct entry of the active agent into the systemic and future patient–physician relationships. burden.and second-generation antipsychotics. Not all interventions and/or formulations can complicate management and compromise future care as have received U.2 are particularly frightening for patients. Oral formulations of most first.26 olanzapine. and/or may need more time to regain control away from other patients Locked seclusion If patients are considered an imminent danger to others but not themselves.or alcohol-abuse problem. Advantages and disadvantages of non-pharmacologic interventions for agitation.

the medication. slow Haloperidol24 2–6 hours tablets/ route and can improve patient onset of action. the effect sizes were comparable to those observed in in 30–60 minutes. Enters alveoli for rapid respiratory distress entry into arterial circulation Oral Standard Less invasive than intramuscular Require patient cooperation. which second-generation antipsychotics. enter systemic Olanzapine27 ~6 hours disintegrating and can improve patient experience.28.30 This can be beneficial for use for this indication would be considered off label. were demonstrated in two Phase III clinical trials.38. one in risperidone. sublingual asenapine was efficacious.33. rapid absorption.31 swallowed. enter systemic Olanzapine27 5–8 hours capsules/ experience circulation via portal system resulting Risperidone30 ~1 hour solution in potential for erratic absorption.36 However. needs Sublingual 0. Aripiprazole28 3–5 hours can be diverted (“cheeking”) Ziprasidone26 6–8 hours Orally Less invasive than intramuscular route Slow onset of action.27. placebo-controlled trial for acute for agents administered via intramuscular injection (Table 3). however. as with in entry to the systemic circulation via the portal system. Managing Schizophrenia and Bipolar Disorder Agitation Table 3. sublingual asenapine is absorbed schizophrenia and the second in bipolar mania.37 It has recently been similar efficacy and safety at the same doses.33. In absorption can be erratic.35 absorption into the systemic circulation with peak plasma which is approved by the FDA for the treatment of schizophrenia levels being reached within two minutes of administration. sublingual dissolve with saliva in the mouth and can be swallowed asenapine is not approved by the FDA for acute agitation and its without additional liquid. administration results advantage of avoiding first-pass metabolism. double-blind.31 and for manic/mixed episodes associated with bipolar disorder. with an effect Orally disintegrating formulations of olanzapine. and aripiprazole have been developed.5–1.Zeller et al.35 Administration via this route has the analogous studies of intramuscular injection of antipsychotics or Volume XVII. with absorption taking place lower in the gut. Intranasal 10 minutes route and can improve patient midazolam32 experience.32 All Loxapine is a first-generation antipsychotic. treatment requires patient cooperation. this method of administration does which is approved by the FDA for the acute treatment of not improve time to onset as the medication must still be agitation associated with schizophrenia or bipolar I disorder.39 In these in the oral mucosa and peak plasma concentration is reached studies. and aripiprazole. Advantages and disadvantages of different routes of administration. mitigated in part by the avoids first-pass metabolism friability of the tablet Intranasal Less invasive than intramuscular Requires patient cooperation. size comparable to that observed in prior studies of intramuscular risperidone. swallowed. no. This results in rapid atypical antipsychotic that is available is sublingual asenapine. suitable for patients with dysphagia Buccal/ Less invasive than intramuscular Requires patient cooperation.35 patients with dysphagia and also in patients who might divert A recent addition to the armamentarium is inhaled loxapine.5 hours sublingual route and can improve patient to be taken correctly so that it is not asenapine35 experience. patient Invasive. circulation via portal system resulting Risperidone30. however. 2 : March 2016 169 Western Journal of Emergency Medicine . Time to Administration peak plasma route Advantages32 Disadvantages32 Examples concentration Intramuscular Rapid systemic entry. The efficacy and safety of inhaled loxapine for acute agitation In contrast to the orally disintegrating tablets of olanzapine.27. However. rapid absorption. avoids first-pass metabolism antipsychotics are available. which has been three of these orally disintegrating antipsychotic formulations available for many years as an oral formulation and has an are bioequivalent to the regular oral tablets and provide established safety and efficacy profile. can damage patient– Haloperidol24 ~20 minutes cooperation not necessary physician relationship Olanzapine27 15–45 minutes Aripiprazole28 1–3 hours Ziprasidone26 60 minutes Inhaled Less invasive than intramuscular Requires patient cooperation Loxapine31 2 minutes route and can improve patient Bronchospasm/ experience.34 reformulated at a lower dose as an inhaled powder that can Another orally disintegrating tablet formulation of an be directly administered to the lungs.28. agitation. all oral medications.34 1–2 hours tablets Less potential for diversion (“cheeking”) in potential for erratic absorption Aripiprazole28 3–5 hours vs standard tablets/capsules. and onset of action is slower than a randomized.

including fewer of agitation: consensus statement of the American Association injuries. MD. In children. Knox DK and Holloman GH Jr. patient-centered approaches result in 2. which increase the options 10 minutes after inhalation.Managing Schizophrenia and Bipolar Disorder Agitation Zeller et al. ‘ which was believed to Med. for Emergency Psychiatry Project Beta Psychopharmacology and reduced resource use and costs. PA. Copyright: © 2016 Zeller et al. and is only to improve the overall patient experience. See: http://creativecommons. inhaled. could be perceived as potential sources of bias. The psychopharmacology improved short. 2012. thereby potentially available through a restricted program under a risk-evaluation improving future cooperation between patients and and mitigation strategy. interpersonal calming skills. Although not FDA approved for acute agitation. staff. even a patient in restraints could sublingual asenapine and intranasal midazolam. and will not treat the underlying psychosis that may szellermd@gmail.1 However. Although using a sedation agent alone might temporarily relieve agitation. or intranasal agents. non-invasive formulations.42. CONCLUSION Agitation represents a significant challenge in the ED. Teva provided a single medical accuracy there has been interest in the potential use of this formulation review of the final draft. 2012. Zeller. West J Emerg Med. are – in the authors’ with dysgeusia being the most common spontaneously reported opinion – essentially now obsolete. as measured by separation for dealing with agitation. The authors were not compensated for this indication.13(1):26-34.13(1):35-40. yet adverse event. inhaled loxapine is restricted to use in hospitals with cooperation from patients. there is the risk Conflicts of Interest: By the WestJEM article submission agreement. West J Emerg Med. should be used whenever possible access to facilities to deal with acute bronchospasm. REFERENCES Time constraints and limited access to specialist psychiatric 1. because effective. Alameda like lorazepam. Overview of project BETA: Best support have in the past led to the somewhat draconian practices in Evaluation and Treatment of Agitation. evidence is also available for refusing treatment. including Anthemis Consulting Ltd. Older interventions. ACKNOWLEDGMENTS Midazolam – a water-soluble. Holloman GH Jr and Zeller SL. intranasally. Use and avoidance of seclusion including triage. improved throughput. diagnosis. means that it is important to address the behavior rapidly and efficiently to ensure the safety of all involved. despite the availability of inhaled loxapine can cause bronchospasm that has the potential these injectable agents. and others at risk. no. The potential for agitation to escalate into aggressive behavior. there have for Emergency Psychiatry Project BETA Seclusion and Restraint been further developments in pharmacologic approaches Workgroup.13(1):1-2. Oakland. 2012. it would not ameliorate hallucinations or Health System 1411 E 31st St.32 Intranasal midazolam is absorbed and retained full editorial control over the content of the paper. Frazer. It is increasingly recognized that more humane. funding sources and financial or management relationships that agitation might quickly return. be engendering the agitation. all authors are required to disclose all affiliations. and and restraint: consensus statement of the American Association medicine choices. such as to lead to respiratory distress and respiratory arrest.0/ emergencies.38. Extrapyramidal adverse events and akathisia more benign.40 Of note. et al. USA. fast-acting benzodiazepine Editorial assistance was provided by Lucy Kanan of – can be administered through various routes. Address for Correspondence: Scott L. 3. putting patients.41 A caveat is that midazolam is chiefly used for sedation and has no antipsychotic effects. however.43 However. spirometry studies indicated available instead. such as intramuscular haloperidol. FDA-approved injectable treatments are were relatively rare. lorazepam. conceivably use voluntarily self-administered medications. that upon awakening. although requiring reason. if one arm can be safely released. including both new agents from placebo on the PANSS-EC. funded by Teva Pharmaceuticals. by the nasal mucosa and avoids first-pass metabolism. better therapeutic alliance. The authors disclosed none. Since their publication in 2012. This is an open access article a setting in which medical staff are working under extreme distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4. the first time point that this was available to patients and physicians. represent the optimal approach.com. however. West J Emerg strategy of “restrain and sedate. were observed as early as and new modes of delivery. measured. At the present time inhaled loxapine is loxapine is self-administered under medical supervision.org/ pressure and dealing with a diverse range of medical licenses/by/4. Pepper D.0) License. 2 : March 2016 . The Project BETA Workgroup. Email: delusions. Western Journal of Emergency Medicine 170 Volume XVII.39 Inhaled loxapine was generally well tolerated. CA 94602. clinical effects. if the psychotic symptoms still persist. Wilson MP. it is the only non-injectable option specifically approved by the unlikely to be suitable in situations where patients are actively FDA for this purpose. thus.and long-term outcomes. guidelines address the complete management of agitation. For this sublingual. Currier GW. It is worth noting that as inhaled healthcare providers. intranasal midazolam induced calming within 15 to 20 minutes.

25. Grant W.23(4):50-1. 30.58(4):331-40.com/pi/pi_abilify. Patient. Rae DS.pdf. Remmerie BM. et al. Citrome L.29(2):290-304. Pfizer Inc. J Psychiatr Res. http://labeling. Zarotsky V. Reducing restraint use in a trauma center emergency room. 35. Manag Care.pdf. Kopecky HJ. et al. 2011.68(12):1876-85. West J Emerg Med. 2014. olanzapine. 2015. Richmond JS. Comorbidity of mental 6. Scale (PANSS) for schizophrenia.pdf. Validation of the Excited treat acute agitation: progress to date.73(16):1783-92. The Overt Aggression Scale: Available at: www.3(2):S22-9.com/assets/Haldol_ Association for Emergency Psychiatry Project BETA De-escalation USPI_0911. 13.49:371-81. 2014. bioequivalence. 2 : March 2016 171 Western Journal of Emergency Medicine . Lindenmayer JP. and delirium in adult patients in the guideline series. 8. in agitated patients. Clin Ther. 2003. 2014. 7. et al. Stowell KR. Reliability and validity of 2014. 29. 5. Alternative delivery systems for agents to 15. et al.org. Otsuka Pharmaceutical Company. 2013. of the agitated patient: consensus statement of the American Available at: www. 2014. Mohaupt SM. 36. Actavis Inc. Batt RJ. Jhee SS. Florence P. 2002. Ann Emerg Med. risperdal. departments. A review of agitation in mental illness: treatment 20. Teva Pharmaceuticals USA I. Wilson MP.com/ShowLabeling. Carpenter D. emergency department.lilly. Available at: www. Zun LS. 2014. 14. 2012. Harman HJ. no. Rapidly disintegrating 16. 2014. Association for Emergency Psychiatry Project BETA Medical Available at: pi. Opler LA. et al.67 Suppl Nurs Clin North Am. Clin Ther.adasuve. 2010.com/us/zyprexa-pi. Pines JM. 2015. Thyssen A. Weiss AP. Psychometric testing of the Agitation Severity Scale 2012. 2015. 34. 2015. children and young people in primary and secondary care.69(4):301-23. Treatment of behavioral emergencies 2005. Geodon Prescribing Information. Adasuve Prescribing Information. Rauch SL. 2012. West J Emerg Med. 2007. 2015. 2003. quiz 110-2. Psychiatric evaluation oculogyric crisis and torticollis with intramuscular haloperidol.pfizer. Evaluation Workgroup.actavis. Swift RH. Accessed Sep 11.com/PDF/AdasuvePI.pdf. 2015. Silver JM and Yudofsky SC. Haldol Prescribing Information. Cappelleri JC. Validation of the aripiprazole for agitation: a quantitative review of efficacy and safety. Adv Emerg Nurs J.and practice-related 19. 1991. Schizophr Res. 2012. 2004. Sep 11. Pratts M. Outcomes. Volume XVII. West J Emerg Med.9:18. Janssen Pharmaceuticals. 2012.41:263-306. Currier GW.32(3):403-25. adults. Remmerie B.13(1):17-25. Risperdal Prescribing Information. tablet disintegration time. Janssen Pharmaceuticals.13(2):261-76. disorder: a summary of ten phase I clinical trials assessing taste. Ann Emerg Med. Morrow T. 33. Van Schaick EA. Clin Ther. Kopecky CR. Sep 11. 1998.37(10):1434-7. J Clin Psychiatry. et al. J Psychiatr Pract. Comparison of intramuscular ziprasidone. 2006.uk/guidance/cg185. Lechat P. Results from disorder: the assessment and management of bipolar disorder in the Epidemiologic Catchment Area (ECA) study. Saphris Prescribing Information. Nordstrom K and Allen MH.janssenpharmaceuticalsinc. 1987.36(2):87-95. The expert consensus management of pain. Behavioural Activity Rating Scale (BARS): a novel measure of activity J Clin Psychiatry. Valladares A.com/assets/ the Overt Agitation Severity Scale in adult psychiatric inpatients. Barr J.aspx?format=PDF&id=584. et al. Clinical practice guidelines for the 23. 2005. Pharmacokinetic EC) in a naturalistic sample of 278 patients with acute psychosis comparison of fast-disintegrating and conventional tablet formulations and agitation in a psychiatric emergency room.nice. Systematic reviews of assessment pi. Component of the Positive and Negative Syndrome Scale (PANSS.13(1):3-10. Accessed overview and guiding principles. Strout TD. Berlin JS. Old drug in new package promises to calm the agitated. 2015. JAMA.janssenpharmaceuticalsinc. Puntillo K. Managing Schizophrenia and Bipolar Disorder Agitation 4. Available at: www. Available at: 18. 1990. Medical evaluation and Accessed Sep 11. et al. Fiszbein A. Brown E. 2013.36(3):250-70. Accessed Sep 11. A single-dose. 28. Chang G. Available at: packageinserts.13(1):11-6. and tolerability. Accessed Sep 11. et al. for acute presentation behavioral management patients in the Accessed Sep 11. Eli Lilly and Company. Fraser GL. 2013.Zeller et al. Cole R.68(2-3):331-7.60(2):162-71. 2011. 17.264(19):2511-8. Harrigan EP. Zeller SL and Rhoades RW. Bipolar disorders with alcohol and other drug abuse.11 Suppl 1:5-108. 2015. guidelines and current therapies. et al. Zyprexa Prescribing Information. agitation. Fishkind AB. Schizophr Bull. Workgroup.com/data_stream. triage of the agitated patient: consensus statement of the American 27. 31. et al. Inc. Health Qual Life of risperidone in healthy volunteers. et al. J Neuropsychiatry Clin Neurosci. 2015. 11. intensive care unit. The financial consequences determinants of emergency department length of stay for patients of lost demand and reducing boarding in hospital emergency with psychiatric illness. Accessed 22. Montoya A. Allen MH. Baker RW. Lizan L. Farmer ME. Regier DA. Kay SR. Accessed Sep 11. et al. Ann of the agitated patient: consensus statement of the American Pharmacother. Available at: Evaluation Workgroup.asp?product_group=1908&p=pi. Association for Emergency Psychiatry Project BETA Psychiatric 26. Abilify Prescribing Information.bms. et al. Inc. or 12. The Positive and Negative Syndrome 2007. D’Hoore P. National Institute for Health and Care Excellence (NICE). Psychiatr Q. measures and pharmacologic treatments for agitation. 32. 10. randomized. Delayed onset of 9. Nordstrom K.25:1687-99.pdf. Drugs. et al. 2015. Marder SR. Citrome L. Verbal de-escalation 24. An excitement subscale risperidone in subjects with schizophrenia or schizoaffective of the Positive and Negative Syndrome Scale. Crit Care Med. 10:13-21 21. Yudofsky SC. Hilton JA.

Review: Limited evidence on effects of haloperidol alone randomized. 2012. et al. aggression or agitation (rapid tranquillisation). Haloperidol for psychosis-induced Psychiatry. 1996. 1980. Zisook S and Click MA Jr. Pharmacol Ther. Riesenberg RA. 2014.9:235- the ambulatory treatment of acute schizophrenic episodes. Evid Based Bipolar Disord. no.15(6):365-78.198(1):51-8. Kwentus J. Rapid acute midazolam and sufentanil premedication in pediatric outpatients. 43. 2 : March 2016 . Cochrane Database 39. Zedie N. Evaluations of loxapine succinate in alternative to injectable agents. Lesem MD. Citrome L.59(3):341-8. 41. 2012. for rapid tranquillisation in psychosis-induced aggression. Tran-Johnson TK. double-blind. Western Journal of Emergency Medicine 172 Volume XVII. Br J 42. 2013. randomised.16(2):47. placebo-controlled study of inhaled loxapine. Acta Psychiatr Scand. of agitation in patients with bipolar I disorder: a multicenter. Ther Clin Risk Manag. Wagner BK. Citrome L. Int 45. Clin treatment of agitation in individuals with schizophrenia: multicentre. et al. Adams CE. Comparison of intranasal 38.14(1):31-40.11:CD009377. Powney MJ. placebo-controlled trial of sublingual asenapine for 40. Ment Health. placebo-controlled clinical trial with inhaled loxapine. 2013. Pharmacopsychiatry. Amory DW. Rapid acute treatment Syst Rev. schizophrenia and bipolar disorder: focus on inhaled loxapine as an 37. et al.Managing Schizophrenia and Bipolar Disorder Agitation Zeller et al.130(1):61-8. Riesenberg RA. Marandi M. Jones H. 2011. Addressing the need for rapid treatment of agitation in acute agitation.